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ABSTRACT 
Title: 
 Functional Evaluation In Pulmonary Tuberculosis Sequelae Patients In a 
Tertiary Care Centre – Chengalpattu 
Background:  
 Pulmonary Tuberculosis can cause chronic impairment of lung function even after 
completion of anti-TB treatment. Several   factors predict the deterioration of pulmonary 
function in treated cases. The time course for change in pulmonary function and risk 
factors have not been well studied so far. 
Aim & objective: 
 The present study aimed to investigate the trends in changes in pulmonary 
function and   factors associated with the sequelae changes in lung in patients who were 
treated for pulmonary Tuberculosis. 
Materials & method: 
 120 subjects both male and female of age 30-60 years who had completed anti-TB 
treatment 18 months back and within 5 years of completion of treatment were included in 
the study. Pulmonary function analysis was done by Spirometry. FVC, FEV1, FEV1/FVC 
were taken for analysis. 
 
Results: 
 The pattern of lung function impairment observed in the study were restrictive and 
mixed pattern in majority of subjects, only 13 out of 120 subjects had normal pattern in 
spirometry. The impairment of lung function was found to increase incrementally with 
increase in lag time, number of episodes of treatment and duration after completion of 
treatment.  
Conclusion: 
 As we have limited resources for the management of restrictive and mixed pattern 
of impairment it is essential that for patients with significant respiratory symptoms and 
multiple risk factors, periodical assessment of pulmonary function should be done to 
monitor the progress of lung function. This also helps in early intervention like 
pulmonary rehabilitation to improve the quality of life in treated pulmonary Tuberculosis 
patients. 
Keywords: 
Pulmonary Tuberculosis sequelae, Spirometry, Restrictive pattern and Mixed 
pattern of Lung function impairment. 
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INTRODUCTION 
 
 Tuberculosis among much other chronic illness is still one of the major 
causes of morbidity and mortality affecting human beings since immemorial time. 
Pulmonary TB seems to have never disappeared in India since Robert Koch 
identified the causative agent in 1882.(1) Even today we get patients affected by 
Pulmonary TB with all the effective control and preventive measures taken over the 
years. Not only the medical implication but also the social and economic impact of 
TB has been enormous. 
  According to Global Tuberculosis report 2014 the prevalence of Pulmonary 
TB worldwide is around 9 million and in India the incidence is 2.2 million and 
prevalence is 2.8 million cases. (2) 
  There are many studies which focused on the pathophysiology, diagnosis, 
and treatment of Pulmonary TB but only a few studies were done so far on the after 
effects of PT infection in lungs. 
  In the few studies that are being done on evaluation of Lung functions in PT 
Sequelae patients there are concrete evidences stating that there is permanent 
functional deterioration in these patients. 
  Many studies say that the obstructive pattern of lung damage is the 
commonest finding. But recent studies say that there are more number of patients 
with restrictive and mixed pattern of damage. (3,5) 
 
2 
 
According to previous studies the changes are more pronounced during 13-
18 months after completion of anti-TB treatment (3,4) In our area where people seek 
medical help at a very late stage, there is involvement of both bronchi & 
parenchyma leading to extensive damage of both. It is important to identify patients 
with deterioration of pulmonary function after the completion of treatment because 
it affects the quality of life of the patients to a great extent. 
  This evaluation can be done by an easy and accessible technique called 
SPIROMETRY. 
TUBERCULOSIS 
  The word Tuberculosis was derived from the Latin word “TUBERCULA” 
meaning small lump. (6) 
HISTORY  
  TB appears to be as old as humanity itself. Skeletal remains of human being 
affected by TB which was dating back to 8000 BC was found in Germany. Ancient 
Hindu and Chinese writings documented the presence of disease. Best proof of TB 
in ancient world has come from mummy of an 8yr old boy who lived 700 AD 
showed evidence of Pott’s disease in X-rays and smear. (7)   
CAUSATIVE AGENT 
  It was Robert Koch who was the one to demystify the cause of TB by 
identifying the bacilli in 1882. (1)  
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  Pulmonary TB is commonly caused by Mycobacterium Tuberculosis which 
are Gram positive bacteria of about 0.2 to 0.6 micro meter by 1.0 to 10 micrometre 
in size. They survive best under temperature of 30ºc to 39ºc. They are obligate 
pathogens and they cannot multiply outside human or animal body. 
   The bacilli can remain viable for many years in tissues of even healthy 
people. It runs a chronic and protracted course when they produce a disease. (6) 
TRANSMISSION   
  TB bacilli can affect almost all the organs in the human body, but lungs is 
the commonest portal of entry in many cases. 
  Pulmonary TB is clearly an air borne disease and is caused by inhalation or 
droplet nuclei with 1 to 3 TB bacilli in it. These droplets are released into the 
atmosphere by an infected person through coughing, sneezing, even while speaking. 
 The patients who has productive cough and whose sputum is smear positive 
for bacilli, they discharge numerous droplet nuclei with numerous bacilli in it. The 
common risk factor for transmission is poor health, poor socioeconomic status, poor 
sanitation and crowded living conditions. (7) 
PATHOGENESIS  
 After entry into the lungs the TB bacilli evoke immunity within 2 to 8 weeks 
of infection in a normal healthy individual. 
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 The alveolar macrophages get activated and release interleukins which in 
turn stimulate T cells to release interferon gamma. These activated T lymphocytes 
forms a granuloma within which the bacilli are sequestered as dormant foci. 
 In 90% people provided they have adequate cell mediated immunity, these 
bacilli remain as dormant foci, i.e. these people are infected but not diseased. This is 
called primary infection or primary tuberculosis. 
 If any defect in immunity arises some people may have an early progressive 
disease within 5 years of exposure. Others may experience recrudescent disease 
even after several decades. This is called reactivation or post primary tuberculosis. 
 This reactivation of the dormant bacilli may occur commonly in conditions 
like diabetes mellitus, HIV, chronic renal failure, vitamin D deficiency. (7,8,9) 
STAGES OF PATHOPHYSIOLOGY 
STAGE I :  
  TB bacilli are engulfed by alveolar macrophages. There is no growth of 
bacilli inside the macrophages. 
STAGE II: (symbiotic stage)  
  It occurs 7 to 21 days after infection. There is growth and multiplication of 
bacilli within the macrophages in a logarithmic scale without damage to the host. 
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STAGE III (caeseous necrosis stage): 
  It is a delayed type of hypersensitivity. The activated T cells kills the bacilli 
laden macrophages forming a caseation. The bacilli can still survive but cannot 
multiply inside the caeseous material due to anoxia, acidic pH. 
STAGE IV: 
  Cell mediated immunity of the host plays a major role in this stage. If the 
immunity is good, the bacilli are destroyed. If the immunity is poor, then the bacilli 
escapes from the caseation and enters lymph nodes and from there through the 
lymphatic circulation it enters blood circulation. 
STAGE V: 
  Liquefaction of caeseous centre occurs and bacilli for the first time multiply 
extra cellularly outside the macrophages and through haematogenous spread it is 
taken to various other organs. 
  At the same time tuberculin like products are released by bacilli causing 
necrosis and erosion of bronchial walls and a cavity is formed. Now the bacilli enter 
into the bronchial tree and spreads to the other parts of the lung and also to outside 
environment infecting other people. (11,12,13) 
CLINICAL PRESENTATION 
  Patient often shows a composite picture in 4 to 6 weeks after infection, i.e, 
during primary TB, most of the patients are asymptomatic or may experience 
minimal symptoms like fever and malaise. Ordinarily until disease is far advanced 
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the symptoms are minimal and the frequency of symptoms also differs whether the 
patient has primary or reactivation TB. 
  During reactivation stage productive cough with sputum and hemoptysis 
occurs especially during liquefaction stage. (7) 
TB IN OLD AGE 
  The picture differs in old age compared to young adults. They present more 
commonly with dyspnoea and significant co morbidities. The typical symptoms like 
fever and hemoptysis are less likely to manifest in old age. (13) 
PULMONARY TB & PATTTERN OF DAMAGE IN LUNGS 
PATHOGENESIS OF OBSTRUCTIVE AIRWAY DIEASE 
  The bronchial tree is affected by any one of the following mechanisms 
a) Most commonly the tracheo-bronchial lymph nodes compress the brochi. If this 
obstruction is complete the lung parenchyma distant to it may be atelectatic. If 
this obstruction is incomplete, it acts like a ball-valve causing obstructive 
emphysema. 
b) Implantation of organism from infected sputum causes inflammatory changes in 
trachea-bronchial tree. If the patient has good immunity this results in increased 
mucus production causing obstruction or the inflammatory cells may release 
cytokines which cause destruction of bronchial wall causing bronchiectasis. 
c) Erosion of lymph nodes into trachea bronchial tree can cause bronchiectasis. 
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d) Direct spread from adjacent parenchyma or spread by haematogenous route may 
occur. 
 All these mechanisms lead to stenosis of bronchial tree despite of treatment 
there by leading to collapse of dependent parts of lung. (14,15) 
 PATHOGENESIS OF RESTRICTIVE LUNG DISEASE  
  In majority of patients the initial focus subsides with cicatrisation, scar 
formation and calcification even when their natural immunity evades the disease. If 
the person is exposed to repeated episodes of extensive PT the infected parenchyma 
heals with fibrosis causing loss of lung tissue. 
  Recently the role of matrix metalloproteinases in destruction of lung tissue is 
being proposed by many studies. Lung extra cellular matrix is formed by fibrillary 
collagen which is highly resistant to enzymatic cleavage except only matrix 
metalloproteinases which can digest all the components of extra cellular 
matrix.(7,14,15) 
  P.T.Elkington et al has proved in their studies that in TB affected lungs the 
alveolar macrophages express matrix metalloproteinases – 1 & 9. There is also 
evidence of decrease in tissue inhibition of matrix metalloproteinases (TIMPS). 
These two factors result in digestion of extra cellular matrix substances thereby 
causing destruction of lung tissue. (28,30) 
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CHANGES IN SMALL AIRWAYS  
  The patency of small airways is maintained by surrounding parenchyma 
which provides a radial traction of bronchioles. 
  When the extracellular matrix in the surrounding parenchyma is destroyed by 
fibrosis the radial traction is lost and there may be distortion and narrowing of small 
airways. (16) 
RESPIRATORY SYSTEM  
  The structure of respiratory system is unique to suit its primary function of 
transport of gases in and out of the body. 
ANATOMY 
  Airflow through respiratory system is by 3 interconnecting structures – upper 
airways, conducting airways and alveolar airway (also called as lung parenchyma). 
UPPER AIRWAY 
  It includes nose, mouth, pharynx and larynx. 
CONDUCTING AIRWAYS 
  It starts from trachea and branches out 23 times till it reaches alveolar sacs. 
The first 16 generation form the conducting zone and it includes large and small 
bronchi, small bronchioles and terminal bronchioles. 
  This structure consists of a lining mucosa, secretory cells, smooth muscles in 
their walls and an enveloping connective tissue interspersed with cartilage. Towards 
9 
 
terminal bronchioles there is decrease in cartilage and absence of secretory cells, 
but the smooth muscles in their walls are prominent. 
ALVEOLAR AIRWAY (LUNG PARENCHYMA) 
  This includes last 7 generations and made up of transitional respiratory 
bronchioles, alveolar duct and alveoli. 
  There are around 300 million alveoli in human lungs. The surfactants 
released by alveolar cells decreases the surface tension. Interstitium is a 
microscopic anatomical space bound by basement membrane of epithelial cell of 
alveoli and endothelial cell of pulmonary capillaries. It consists of collagen and 
reticulin fibers which create a helical network of connective tissue around the 
alveoli and respiratory airway walls. 
  The lungs are conglomerate of alveoli bounded by chest wall and diaphragm 
and lie within pleural cavity. The average volume of lung is 3.5 litres and they 
weigh 900gms approximately. 
  Both the lungs and chest wall are elastic in nature and they can expand and 
recoil. This elasticity is conferred by elastic tissue in airway and alveolar wall, and 
also by connective tissue in the inter alveolar space and by surfactant. (16,18,19) 
RESPIRATORY UNIT  
   It is composed of respiratory bronchiole, alveolar ducts and alveoli. The 
alveolar wall has network of interconnecting capillaries. So that exchange of gases 
occurs between alveoli and capillaries. (20) 
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Figure 1: Respiratory membrane  
 
   This is the structure through which exchange of gases takes place.  
  The layers of the structure are  
1) Fluid layer containing surfactant 
2) Layer of alveolar epithelium 
3) Epithelial basement membrane 
4) Thin interstitial space between alveoli and capillaries 
5) Capillary basement membrane 
6) Endothelial cell layer of capillaries (20) 
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INSPIRATION AND EXPIRATION 
  Inspiration is an active process. The muscles involved are diaphragm, 
external intercostal muscles, sternocleidomastoid muscle, serratus anterior muscle, 
scalene muscle. When these muscles contract they increase the lung volume. 
  The intra pleural pressure becomes more negative from -2.5mm Hg to  
-6mmHg during inspiration. This is created by expansion of chest wall which pulls 
the lung along with it with such great force. 
  Expiration during quiet breathing is passive. At the end of inspiration, the 
inspiratory muscles relax and also due to elastic recoiling of lung the chest wall is 
pulled back to its original position. Now the intra pleural pressure becomes slightly 
positive and air flow out of the lungs. 
  At the end of expiratory process, the recoiling force of lungs and the 
recoiling force of the thoracic cage balance each other and now the intra pleural 
pressure becomes -2.5 mm Hg. (17) 
PULMONARY DEFENSE MECHANISM  
  At all levels of respiratory tract specific and nonspecific defense mechanisms 
exists to protect the respiratory system. 
  Epithelial cells of conducting airway secrete IgA, surfactant protein A and B, 
various proteases, peptidases that kills the microbes directly. They also secrete 
chemokines and cytokines that attract immune cells there by killing the microbes 
indirectly. 
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  The dichotomous branching of airway traps the smaller particles and clears it 
by coughing and mucociliary escalation. 
  The alveoli have pulmonary alveolar macrophages which secrete cytokines 
to attract the granulocyte and initiate immunological reaction. But this action is a 
two edged sword for the pulmonary alveolar macrophages may also release 
lysosomal products in extracellular space to cause inflammation of the Interstitium 
that heals with fibrosis. (13,17) 
 
PATHOGENESIS OF OBSTRUCTIVE LUNG DISEASE  
  Inflammation of airways or bronchial hyper reactivity may lead to increased 
mucus production, decreased ciliary action and loss of elasticity of bronchial wall. 
These lead to obstruction of airways. (19) 
 
PATHOGENESIS OF RESTRICTIVE LUNG DISEASE  
  Normally interstitial space has minimal connective tissue, extracellular 
matrix and minimal inflammatory cells in them. This allows efficient gas exchange 
between alveoli and capillaries. If any inflammation of interstitium occurs, the 
lungs responds to the damage and try to repair the damage. If the inflammation 
persists or if there is imperfect repairing process occurs, then this may lead to 
permanent damage of lung parenchyma resulting in restrictive lung disease. (19) 
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LUNG VOLUMES AND CAPACITIES 
  Lung volume determinants usually include the vital capacity and its 
subdivision along with functional residual capacity. From these two basic 
measurements the remaining lung volumes and capacities can be calculated. 
  There are four lung volumes. They are 
1. Tidal volume is the volume of air inspired or expired during quiet breathing 
and is about 500ml. 
2. The amount of air inspired with maximum inspiratory effort above the 
normal tidal volume is called inspiratory reserve volume: It is about 
3000ml. 
3. The expiratory reserve volume is the volume of air expired with maximum 
expiratory effort after the normal tidal expiration: This normally amounts to 
about 1100ml. 
4. The volume of air remaining in the lungs after the forceful expiration is 
known as residual volume: It is normally about 1200ml. 
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Figure 2: Lung volumes and capacities 
 
The pulmonary capacities are 
1.  The maximum amount of air inspired after completing the tidal expiration is 
defined as inspiratory capacity and is about 3500ml. 
2.  The functional residual capacity is the amount of air remaining in the lung 
at the end of normal expiration and is about 2300ml. 
3.  The vital capacity is the maximum amount of air expired forcefully after a 
maximum inspiratory effort and is about 4600ml. 
4.  The total lung capacity is the volume of air present in the lung after a 
maximum inspiration and is about 6 litres. (20) 
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INDICES BASED ON VOLUME 
1) FORCED VITAL CAPACITY (FVC) 
  It is defined as the maximum volume of air expired forcefully and rapidly 
after a maximal inspiration. 
  Normally FVC equals VC or FVC and VC should be within 200ml of each 
other. When FVC is < 80% of predicted value it is abnormal. But low FVC is a 
nonspecific finding. 
  FVC may be low in both obstructive and restrictive disorder. But in 
restrictive disorder FVC is too low compared to FEV1. 
2) FEV1 
  It is the volume of air expired in first second of an FVC manoeuvre.  When it 
is < 80% of predicted value it is considered to be abnormal. It is also a non specific 
measurement. 
  FEV1 may be low in both obstructive and restrictive disorders, but in 
obstructive disorder FEV1 is considerably low when compared to FVC. 
3) FEV1 / FVC ratio (or) FEV1% 
  The FEV1 expressed as a percentage of VC or FVC. Normal value is 70% 
 FEV1% = (FEV1/FVC) × 100 
  The relationship is a component of most lung function reports. 
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4) FEF 25-75% 
  Forced expiratory flow over the middle half of the FVC manoeuvre. It is an 
indicator of status of medium to small airways. Normal value for healthy young 
adults is around 4 to 5 litres per second. When it is measured in percentage the 
normal value is 65% of predicted value. 
5)  MAXIMUM VOLUNTARY VENTILATION (MVV) 
It is the maximum volume of air expired in a specific period of time (12 sec 
for normal subjects). It tests the overall function of the respiratory system. It is 
influenced by airway resistance, respiratory muscle, compliance of the lung and 
chest wall and ventilatory control mechanisms. Values in healthy young men 
average between 150 – 200 L/min. MVV is decreased in patients with moderate or 
severe obstructive disease. MVV may be normal in patients who have restrictive 
pulmonary disease. They can compensate by performing the MVV manoeuvre with 
VT and breathing rates. 
6)  SLOW VITAL CAPACITY 
The volume of gas measured from a slow, complete expiration after a 
maximal inspiration, without forced or rapid effort is known as vital capacity. It is 
also referred to as the slow vital capacity, distinguishing it from forced vital 
capacity. 
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7) PEAK EXPIRATORY FLOW (PEF) 
The maximal expiratory flow achieved during a maximum forced expiration 
initiated at TLC. PEF  primarily measures large airway function. Effort dependence 
of PEF makes it a good indicator of patient effort during spirometry. It is 
particularly useful for monitoring asthma patients at home. (18,21,22) 
INDICES BASED ON TIME  
FORCED EXPIRATORY TIME (FET) 
The time taken to expire a specified portion of the forced vital capacity                       
is known as forced expiratory time (FET). If it is > 4 second it indicates some 
degree of airflow obstruction. (22) 
PULMONARY FUNCTION TESTS 
 Pulmonary function tests are age old and very important tests to assess the 
function of respiratory system in a person. They provide knowledge about the 
clinical condition, diagnosis and prognosis of a disease. 
 Normally a person attains maximal lung function around 20 to 25 years of 
his / her age. After 30 to 35 years of his / her age there is decline in lung function. 
 The lung function decline to a moderate extent even before clinical 
symptoms and signs develop. So the assessment of severity of disease is difficult 
with symptoms and signs alone, which may lead to inadequate treatment and 
control of disease. So early measurement of lung function test is very important for 
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early intervention and control, and also to monitor the progress of the 
disease.(19,21,23) 
 The important factors that determine the ability of lungs to exchange gases 
effectively are as follows. 
Factors contributing for ventilation: 
1) The diaphragm and other thoracic muscles which are essential for 
expanding the lungs and thoracic cavity to create a sub atmospheric 
pressure. 
2) The patent airways which allows the gas to reach the alveoli. 
Factors determining the diffusion and perfusion of lungs: 
1) The intact and effective respiratory membrane for the diffusion of oxygen 
and carbon dioxide across them. 
2) The normal functioning of cardiovascular system to provide adequate 
blood supply to the lungs. 
The pulmonary function tests provide valuable information about all the 
above processes of ventilation, diffusion and perfusion. (14) 
Based on the aspects of lung function they measure, the pulmonary function 
tests are categorized as: 
1) Airway function test – VC, FVC, FEV1, PEFR, FEF 
2) Lung Volume and Ventilation Test – FRC, TLC, Minute ventilation 
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3) Diffusion Capacity Test – DLCO 
4) Blood Gas and Gas Exchange Test – ABG, pulse oximetry, 
capnography 
5) Cardiopulmonary Exercise Test – Test with exhaled gas analysis, Test 
with blood gas analysis 
6) Metabolic Measurement – resting energy expenditure, substrate 
utilisation 
Among these the airway function and lung volume are almost always 
measured with spirometry (21) 
SPIROMETRY 
 Spirometry is a basic, easiest but powerful tool that can detect and 
differentiate the lung disorders and is also used as a tool for follow up of patients 
with pulmonary disorders. It is very useful in determining the pattern of lung 
dysfunction. 
 However, spirometry must be performed correctly because it may yield a 
false positive response if performed poorly. 
HISTORY OF SPIROMETRY 
 In 1800 John Hutchinson developed a simple water seal spirometer with 
which he measured a parameter what he called as vital capacity / vital breath. He 
observed that vital capacity was related to standing height of the patient. He also 
developed a table to estimate expected vital capacity for a healthy person. 
20 
 
 Borelli in 1679 measured the volume of air inhaled by a single deep breath.  
In 1788 the need for temperature correlation was pointed out by Goodwyn. 
 In 1800 Davy measured the residual volume by gas dilution method.  
In 1831 Thackrah showed that the volume of air is less in women than men.  
In 1956 Dubois and colleagues developed a method called whole body 
plethysmograph. 
In 1930s Barach observed that the patients with asthma exhaled more slowly 
than healthy individuals. He was the one who noted that airflow out of the lungs 
was important in determining obstructive airway disease. Subsequently he used 
kymograph to display VC changes as a Spirogram. 
In 1950 Gaensler used a micro switch in conjunction with water sealed 
spirometer to time FVC. He observed that healthy individual exhaled approximately 
80% of their FVC in 1 second and almost all of FVC in 3 second. He used the FEV1 
to assess airway obstruction. 
In 1955 Leuallen and Fowler demonstrated a graphical method to assess air 
flow. They measured airflow between 25% and 75% points on a forced expiratory 
spirogram. This was described as maximal mid expiratory flow rate (MMFR) or 
forced expiratory flow 25-75% (FEF 25-75%). 
In the late 1950s Hyatt and others used the flow volume display to assess 
airway function. The tracing was called maximal expiratory flow volume curve 
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(MEFV curve). By combining this with inspiratory manoeuvre a closed loop called 
flow volume loop (FVL) was displayed. 
In 1960s Wright used peak flow to monitor asthmatics. PEF is measured 
using a flow sensing spirometer / peak flow meter. 
Maximum voluntary ventilation (MVV) was described in 1941. Cournand 
and Richards called it originally the maximal breathing capacity. MVV gives an 
estimation of the peak ventilation available to meet physiological demands.  
Nowadays modern computerized pulmonary function systems allow very 
sophisticated data handling and storage, graphic display of manoeuvres, accurate 
calculation and enhanced reporting method. They include physical transducers, 
analog to digital converters and computer software to process and record the data. 
Microprocessor based portable spirometers are now available. (21) 
TYPES OF SPIROMETERS 
 Based on the principle by which they work the spirometers are of two types. 
I) Volume displacement spirometers 
The amount of air exhaled or inhaled within a certain time is recorded by 
these types of spirometers. The following are widely used volume displacement 
spirometers. 
1) Water seal spirometer 
2) Dry rolling seal spirometer 
3) Bellows spirometer 
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II) Flow sensing spirometers (pneumotachometer) 
They measure how fast the airflows in or out as the volume of air inhaled or 
exhaled increases. The common types are: 
1) Rotating vanes (turbine) 
2) Pressure differential flow sensing spirometer 
3) Hot wire anemometers 
4) Pitot tube flow sensing spirometers 
5) Ultrasound devices. (21) 
STANDARDIZATION OF SPIROMETRY 
According to American Thoracic Society the spirometers are standardized as 
follows: 
           It should record at least FVC and FEV1. 
 It should record a flow volume curve or a flow volume loop or both. 
 It should be able to measure up to 15 seconds for FVC. 
 It should have a capacity of 8 litres. 
 It should measure volume within < 3% error or within 0.05 litres of a 
reference value whichever is greater. 
 It should measure flow within <5% error or 0.2 litres per second whichever 
is greater. 
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 The values given by spirometer are corrected for body temperature, ambient 
pressure and saturated with water vapour (BTPS). 
 It can be calibrated with a 3 litres syringe. (24) 
INDICATIONS FOR SPIROMETRY  
1) To detect presence or absence of lung dysfunction 
2) To assess severity of lung disease 
3) To monitor the disease progression 
4) To assess the efficacy of treatment given 
5) To measure the effects of occupational and environmental exposure of air 
pollutants 
6) To assess fitness of patient prior to surgical procedures. 
7) To quantify the impairment or disability. (19,25) 
CONTRAINDICATIONS FOR SPIROMETRY 
1) Any respiratory infections 
2) Recent myocardial infarction within 1 month prior to the procedure. 
3) Unstable cardiovascular status. 
4) Haemoptysis of any cause. 
5) Pneumothorax 
6) Recent surgeries of eye / thorax / abdomen 
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7) Stress incontinence. 
8) Dementia or confused patient. 
9) Oral or facial pain exaggerated by the mouth piece. (19,25) 
RECORDING OF SPIROMETRY 
 It is recorded both graphically and numerically. Graphically it is recorded as  
1) Spirogram – volume versus time graph 
2) Flow rate versus volume – it can be either  
a) Flow volume curve when only expiratory flow is recorded 
b) Flow volume loop when both expiratory flow and inspiratory flow 
is recorded. (21,22) 
Figure 3 
 Volume vs time graph (spirogram) 
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Figure 4: Flow – volume loop 
 
Flow is plotted on the vertical axis and volume is plotted on the horizontal 
axis.  
Expiratory flow is plotted upward and inspiratory flow is plotted downward.  
Peak flows for expiration and inspiration (PEF and PIF) can be read directly 
and the instantaneous flow (FEF) at any point in the FVC also can be measured 
directly. 
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LUNG DISORDERS AND ITS PATTERN IN SPIROMETRY RESULTS 
 Normal value – FEV1 and FVC >80% predicted value 
- FEV1 / FVC ratio >70% of predicted value 
Obstructive lung disorders 
- FEV1 <80% of predicted value 
- FVC normal or reduced (if reduced usually to a lesser 
degree than FEV1) 
- FEV1 / FVC ratio <70% of predicted value 
Restrictive lung disorder 
- FVC <80% of predicted value 
- FEV1 normal or reduced (if reduced usually to a lesser 
degree than FVC) 
- FEV1 / FVC ratio 70% or > 70% of predicted value 
Mixed function disorder (both obstructive and restrictive) 
-  FVC and FEV1 <80% of predicted value 
- FEV1 / FVC ratio <70% of predicted value 
(31) 
 
 
 
27 
 
Table I: Interpretation of Spirometry data  
PFT 
PARAMETERS 
OBSTRUCTIVE 
PATTERN 
RESTRICTIVE 
PATTERN 
MIXED 
PATTERN 
FEV1 Reduced Reduced / Normal Reduced 
FVC Reduced / Normal Reduced Reduced 
FEV1 / FVC Reduced Normal / Increased Reduced 
  
Figure 5: Interpretation of patterns of lung function impairment 
FEV1/ FVC RATIO 
(25) 
 
  LOW         NORMAL / HIGH 
 
  FVC              FVC 
 
NORMAL   LOW   NORMAL   LOW 
 
OBSTRUCTIVE          MIXED  NORMAL          RESTRICTIVE 
    PATTERN            PATTERN      STUDY       PATTERN 
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REVIEW OF LITERATURE  
Dye C et al in their studies have stated that despite predictions of global 
decline in incidence of pulmonary tuberculosis, still new cases nearing 10 million 
has been reported in 2010 worldwide. This study has reviewed the changing 
relationship between the host i.e. human body and the causative agent i.e. 
mycobacterium tuberculosis that could explain the persistence of TB. Whatever the 
technology used, successful control depends on the social, institutional & 
epidemiological context in which it is applied. (32)  
The chronic impairment of lung function increases with increase in number 
of episodes of tuberculosis. The effect of TB on lung function can be prevented by 
early detection and control of other risk factors such as occupational exposure, 
socioeconomic factors etc. (33)   
On investigating the trends in changes in pulmonary functions and the risk 
factors responsible for deterioration of pulmonary function, it was found that the 
nadir of pulmonary function occurred approximately 18 months after completion of 
treatment for TB. The risk factors included are smear positive disease, extensive 
lung involvement prior to treatment, prolonged treatment, and reduced radiological 
improvement after treatment. So it is important that pulmonary function tests are 
done as a routine follow up especially 18 months after the completion of anti-
tuberculous treatment. (3) 
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Inflammatory tissue damage is the main pathogenesis for destruction of lung 
tissue, the tissue damage is caused by digestion of extracellular matrix substance by 
decreased tissue inhibition of matrix metalloproteinases. (28) 
In progressive tuberculosis patients lung remodeling (i.e. healed cavitation, 
fibrosis,etc.) occurs by dysregulation of granulomatous turnover, liquefaction 
necrosis and pathological scarring. (27)  
TB sequelae changes occur more commonly in young age and men: women 
ratio is 2:1. Systemic complication of pulmonary tuberculosis are not more common 
and main factor in development of sequelae changes is due to local lung tissue 
damage. (35) 
Neeta singla et al in their study on screening for lung function impairment in 
patients with post treatment period of 22 ± 14.7 months had found that 96% of 
patients were found to have abnormal PFT. Out of this 66% had mixed pattern, 19% 
had pure restrictive pattern and 11% had pure obstructive pattern of damage. (36) 
Nefedov et al in their study on functional evaluation of patients with chronic 
fibrocaseous tuberculosis found that lung function defect was found in 96.8% of 
patients under their study. Among these considerable and drastic changes in lung 
volume and capacities occurred in 90.2 patients and mild impairment of bronchial 
patency and pulmonary exchange function in 90.3. (37)   
Clinico physiological examination of patients with destructive pulmonary 
tuberculosis showed that restriction pattern of damage and decline of elasticity of 
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lung tissue is the most common manifestation. The bronchial patency disorder and  
disorders in exchange of gas occurs less common. (38) 
In a study in which spirometry was done in adult treated TB patients 
presenting with dyspnoea, all 3 types of lung function damage viz restrictive, 
obstructive, mixed pattern was found. (39) 
There is high rate of morbidity among cured pulmonary tuberculosis patients 
even 14years after completion of treatment causing deterioration of their Quality of 
life. The predominant impairment are restrictive and mixed pattern disease. (40) 
Pulmonary tuberculosis results in partial reduction of ventilation and 
perfusion. Normal lung function was seen in non cavitary disease. Mild restriction is 
seen in cavitary disease. (41) 
In elderly patients isolated mid or lower lobe involvement is common.   
Consolidation and large opacity mimicking mass is seen in elderly patients. (42) 
All cases of cured pulmonary tuberculosis even though patients are 
asymptomatic, they are prone to have pulmonary function impairment. There is a 
relationship between positive radiological score and severity of defect in lung 
function i.e. greater radiological sequelae implies severe pulmonary impairment. (43) 
Even after completion of successful treatment in non-obstructive cases of 
lung impairment change in vital capacity was found to be 27.7ml/year. Decrease in 
FEV was found in 28.8ml/ year. (44) 
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The accuracy of spirometric measures of FVC and expiratory flow rates in 
diagnosing presence of restrictive impairment was studied by Shaw et al. according 
to this study <60% of patients with a classical restrictive pattern in Spirometry had 
pulmonary restriction confirmed by measurement of lung volumes. (45) 
Interpretation of restrictive pattern identified by means of spirometry can be 
made accurately by incorporating the magnitude of reduction in FVC and 
percentage difference between FEV1 and FVC. 
(46)  
Venkateshiah et al in their study aimed at determining the utility of 
spirometric measurements of FVC, FEV1 and FEV1/FVC ratio in diagnosing 
restrictive pattern. They have concluded that FVC < Lower limit of normal and 
FEV1/ FVC within normal range has a positive predictive value of up to 73.9% in 
diagnosing restrictive pattern. They have also concluded that FVC can be used as a 
criteria to exclude restriction with higher reliability. (47)  
Eric Walter Petura Yone et al had done a study to assess the clinical impact 
of low FEF 25-75% in treated Pulmonary Tuberculosis patients. They had fixed a 
cut off value of 65% for FEF25-75% below which patient was diagnosed to have 
distal airway obstruction. In their study they had a correlation of time lag of >12 
weeks and occurrence of       FEF25-75%  <65% in these patients. (48) 
Evaluation of physical functional capacity in pulmonary tuberculosis 
sequelae patients of age 50-65 years when compared with age matched healthy 
individuals showed a significant decrease in functional capacity in pulmonary 
tuberculosis sequelae patients due to exercise induced hypoxia. (49) 
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A study on Quality of life using SF-36 questionnaire which was conducted in 
a Tuberculosis unit in south India with 436 patients who had completed treatment 1 
year prior to the study has shown that the decrease in Quality of life after the disease 
was associated with age, literacy, income, smoking, alcoholism, persistence of 
symptoms. (50) 
Reduction in functional exercise capacity due to increase in work of 
breathing in chronic respiratory illness makes the patients to be depressed and 
socially isolated. The functional disability and repeated hospitalization decreased 
their efficiency in work and pose a socioeconomic burden. So Pulmonary 
rehabilitation as a multidisciplinary and comprehensive non pharmacological 
intervention has emerged as a recommended standard care for patients. The goal of 
pulmonary rehabilitation is to provide the patients a better quality of life. (51) 
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AIM & OBJECTIVE 
AIM 
To analyze the pattern of lung damage – obstructive / restrictive / mixed 
whichever is commonly occurring in Pulmonary Tuberculosis sequelae patients 
OBJECTIVE 
1) To find the association between Number of Episodes of TB Treatment 
and pattern of lung damage thereafter. 
2) To find the association between Lag Time (time interval between onset 
of symptoms and diagnosis of the disease) and extent of destruction of 
lung tissue. 
3) To assess the progression of damage of lung tissue and its association 
with Time Duration After Completion of Treatment  
 
 
 
 
 
 
 
 
MATERIAL AND 
METHODS 
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MATERIAL & METHODOLOGY 
DESIGN OF STUDY 
Cross – sectional study 
MATERIAL 
120 patients both male & female (male-81 and female – 39) attending 
Thoracic Medicine outpatient department at Chengalpattu Medical College were 
selected for the study. 
INCLUSION CRITERIA 
1) Both male & female 
2) Age 30 -60 years 
3) Released from treatment 18 months prior to the study and within 5years 
after completion of treatment. 
4) Cessation of smoking after diagnosis of Pulmonary TB 
EXCLUSION CRITERIA 
1) Active pulmonary TB 
2) Extra pulmonary TB 
3) MDR TB 
4) HIV positive 
5) Severe respiratory distress 
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6) Bed ridden 
7)  Pregnancy 
8) Diabetes mellitus 
9) Recent myocardial infarction 
10) Cardiac disease like unstable angina 
11) Connective tissue disease 
12) Post thoracic surgery 
13) Chest / abdominal pain /oral / facial pain of any cause 
MATERIAL 
 Easy On PC Spirometry (ndd medizintechnik AG, Zurich, Switzerland) 
Working principle is the Ultrasound flow sensor measures the transit time 
which allows the accurate determination of flow velocity independent of 
temperature, humidity and molar mass of the gas. Since the measuring principle is 
based on a digital measurement technique the sensor requires only one single 
calibration and does not change during the sensor’s lifetime.   
METHODOLGY 
Precautions 
1) 2 sputum samples were taken prior to procedure and sputum negativity 
was confirmed by Zeihl-Neelson technique. 
2) Chest X-ray PA view taken 
36 
 
3) Random blood sugar  to rule out diabetes mellitus was taken 
4) ELISA for HIV done and results verified 
5) Institutional Ethics committee approval was obtained. 
ON THE DAY OF RECORDING 
 Subject was advised to avoid 
1) Full meals 2 hours prior to the test 
2) Alcohol consumption 4 hours prior to the test. 
3) Short acting bronchodilators 6 hours prior to the test 
4) Long acting bronchodilators 12 hours prior to the test 
5) Switch off the mobile phone 
PROCEDURE 
Informed consent was obtained 
Anthropometric measurements - Height and weight of the subject was 
measured. 
SPIROGRAM (OPEN CIRCUIT METHOD) 
 Subject was seated comfortable and relaxed in an armed chair with 
straight back 
 Procedure demonstrated by the investigator 
 Subject was asked to inhale air deeply to fill the lungs 
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 Nose clip is placed immediately 
 Spirette is kept inside the mouth of the patient with lips tightly sealing 
around the spirette 
 Subject is asked to blow out air as fast and as hard as possible i.e., 
BLAST OUT for a minimum of 6 seconds 
 Likewise, minimum of 3 trials done with an interval of 5 minutes in 
between each trial   
 Best of three trials taken for analysis (21) 
FLOW VOLUME LOOP (OPEN CIRCUIT METHOD) 
 Ask the subject to sit comfortably and relaxed in an armed chair with 
straight back 
 Procedure demonstrated to the subject 
 Subject is asked to inhale atmospheric air deeply 
 Nose clip is placed immediately 
 Spirette is kept inside the mouth with lips tightly sealed around it 
 The subject is asked to blow out air as fast and as hard as possible, 
BLAST OUT for a minimum of 6 seconds 
 Then immediately ask the subject to inhale deeply with the spirette still 
inside the mouth (to form a loop) 
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 Minimum of 3 trials done with an interval of 5 minutes between each trial 
 Best of 3 trials taken for analysis (21) 
ACCEPTABILITY CRITERIA: 
According to American Thoracic Society Criteria 
- Effort should be maximal, smooth and cough free 
- Exhalation time should be for a minimum of 6 seconds 
- End of test is indicated by 2-second volume plateau (24, 25) 
REPRODUCIBILITY CRITERIA: 
According to American Thoracic Society Criteria 
-  Two largest FVC   measurements should be within 200ml of each other  
-  Two largest FEV1 measurements should be within 200ml of each 
other(24,25) 
ANALYSIS: 
Percentage of the Predicted values of FEV1, FVC, FEV1 / FVC, FEF25% -75%   
were taken for analysis. 
The pattern of lung function impairment was assessed from spirometry 
results using percentage of the predicted values of FEV1/FVC, FVC
. (25) 
Severity of restrictive impairment of lung function was assessed using 
percentage of predicted values of FVC. (26) 
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SEVERITY OF RESTRICTIVE PATERN  
(BASED ON FVC %) 
 
 Mild restriction – 60 to 80% 
Moderate restriction – 45 to 59% 
Severe restriction - <45%  (25,26) 
Statistical analysis was done by using SPSS 16.0 version. 
 
 
 
 
 
 
 
 
RESULTS 
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RESULTS 
120 subjects (male -81, female – 39) who had completed tuberculosis 
treatment 18 months before the study and within 5 years of completion of treatment 
were participated in the study. 
The following patterns of lung function impairment were obtained by 
spirometry. 
1) Mild restriction pattern 
2) Moderate restriction pattern 
3) Severe restriction pattern 
4) Mixed pattern 
5) Few  had normal study pattern also (13 subjects) 
Anthropometric measurements and lung function parameters were analysed 
by arithmetic mean and standard deviation. 
The mean value of lung function parameters in each pattern of lung function 
impairment was analysed by ANOVA and Chi square test. 
The mean value of lung function parameters were correlated with number of 
episodes of TB treatment, time duration after treatment (months) and lag time in 
days (time duration between onset of symptom and diagnosis) by Spearman’s rho 
analysis. 
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TABLE II 
Descriptive Statistics 
Parameter Min Max Mean ± S.D 
Age 30 60 48 ± 9.2 
Height 139 176 157 ± 8.41 
Weight 35 70 52.9 ± 9.92 
BMI 12.6 34.7 21.55 ± 4.34 
FVC  
 (Percentage of predicted value) 25 99 57.15 ± 16.46 
FEV1 
(Percentage of predicted value) 16 96 57.27 ± 19.39 
FEV1/FVC 
(Percentage of predicted value) 46 120.45 89.09 ± 15.71 
FEF 25-75% 
(Percentage of predicted value) 7 120 41.32 ± 25.97 
 
The above table shows baseline data of study group. 
Anthropometric measurements and Lung function parameters were analysed 
by Arithmetic Mean and Standard Deviation. 
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TABLE III 
Frequency percent distribution of age group 
Age Frequency Percent 
30-40 32 26.6 
41-50 35 29.2 
51-60 53 44.2 
Total 120 100 
 
Maximum number of patients belongs to age group 51 – 60. 
Minimum number of patients belongs to age group 30 – 40. 
 
Figure 6: Frequency percent distribution of age group 
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TABLE IV 
Frequency percentage of Gender distribution of study group 
SEX Frequency Percent 
Male 81 67.5 
Female 39 32.5 
Total 120 100 
 
Among the 120 subjects participated in this study 67.5% were male subjects, 
and 32.5% were female subjects. 
Male : female ratio in this study was around 2:1 
Figure 7: Frequency percentage of Gender distribution of study group 
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TABLE V 
Frequency distribution of different patterns of Lung Function Impairment. 
Diagnosis Frequency (n=120) Percent (100) 
Mild restriction 40 33.3 
Moderate restriction 32 26.7 
Severe restriction 14 11.7 
Mixed pattern 21 17.5 
Normal study 13 10.8 
 
This table shows the distribution of pattern of Lung Function Impairment 
among the study group. 
Figure 8: Frequency distribution of different patterns of Lung Function 
Impairment 
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TABLE VI 
FVC in various patterns of Lung Function Impairment 
Parameters 
Pattern of 
damage 
N Mean ±  S.D Minimum Maximum F Sig 
FVC 
(Percentage 
of predicted 
value) 
Normal 
study 13 89 ± 6.04 80 99 
166.49 0.000* 
Mild 
restriction 40 66.28 ± 5.27 60 80 
Moderate 
restriction 32 51.03 ± 5.91 26 59 
Severe 
restriction 14 38.71 ± 3.81 34 45 
Mixed 
pattern 21 41.67 ± 9.90 25 62 
Total 120 57.15 ± 16.47 25 99 
 
Mean ± S.D value of FVC varies significantly in different patterns of lung 
function study (P < 0.01). 
FVC value decreases as severity of lung impairment increases 
Statistical analysis was done by ANOVA. 
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Figure 9: FVC in various patterns of Lung Function Impairment. 
 
 
 Significant difference in mean value of FVC between normal study and 
restrictive pattern was observed. 
There is significant decrease in mean FVC value between mild restriction 
and severe restriction pattern of lung damage. 
 There is not much difference between mean value of FVC in mixed pattern 
and mean value of FVC in severe restriction. 
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TABLE VII 
FEV1 in various patterns of Lung Function Impairment 
Parameter 
Pattern 
of 
damage 
N Mean ± S.D Minimum Maximum F Sig 
FEV1 
(Percentage 
of predicted 
value) 
Normal 
study 13 88.69 ± 5.00 81 96 
326.78 0.000* 
Mild 
restriction 40 69.72 ± 4.52 60 83 
Moderate 
restriction 32 54.5 ± 6.79 43 66 
Severe 
restriction 14 44.64 ± 4.10 35 51 
Mixed 
pattern 21 26.71 ± 6.61 16 37 
Total 120 57.27 ± 19.40 16 96 
 
Statistical analysis by ANOVA shows that the Mean ± S.D value of FEV1 
varies significantly in different patterns of lung function study (P < 0.01). 
FEV1 value decreases as severity of restrictive pattern increases, but mean 
value of FEV1 is higher compared to FVC in restrictive patterns of lung impairment 
except in mixed pattern. 
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Figure 10: FEV1 in various patterns of Lung Function Impairment 
 
 
 
 The difference in mean value of FEV1 between normal study and restrictive 
pattern is much less compared to difference in mean value of FVC between normal 
study and restrictive pattern. 
Significant decrease in FEV1 Value was observed as severity of lung damage 
increases. 
 Significant difference in mean value of FEV1 between restrictive pattern and 
mixed pattern was observed. 
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TABLE VIII 
FEV1 / FVC in various patterns of Lung Function Impairment 
Parameter 
Pattern of 
damage 
N Mean ± S.D Minimum Maximum F Sig 
FEV1  / FVC 
(Percentage 
of predicted 
value) 
Normal 
study 13 99.92 ± 6.37 90 111 
47.33 0.000* 
Mild 
restriction 40 95.24 ± 7.51 81.58 113.33 
Moderate 
restriction 32 94.84 ± 15.14 50.98 120.45 
Severe 
restriction 14 87.29 ± 6.67 76 97 
Mixed 
pattern 21 63.14 ± 6.05 46 71 
Total 120 89.10 ± 15.71 46 120.45 
 
Statistically significant (P < 0.01) variation was noted in FEV1 / FVC values 
depending up on the severity of lung damage. 
As severity increases the mean value of  FEV1 / FVC decreases. 
But in all range of severity value of FEV1 / FVC is >70% suggesting that the 
pattern of damage was restrictive in nature.  
In mixed pattern mean FEV1/FVC is less than 70% 
ANOVA test was used for analysis. 
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Figure 11: FEV1 / FVC in various patterns of Lung Function Impairment 
 
 
 
Mean FEV1/FVC value is more than 70% indicating the pattern of damage is 
restrictive, but significant decrease in mean value was observed as severity 
increases. 
In mixed pattern the FEV1/FVC is below 70%. 
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TABLE IX 
Comparison of mean ± S.D Values of FVC, FEV1 and FEV1/FVC between 
different patterns of Lung Function Impairment 
 
Parameters 
(Percentage of 
predicted value) 
Mild 
Restriction 
Moderate 
Restriction 
Severe 
Restriction 
Mixed 
Pattern 
FVC 66.28±5.27 51.03±5.91 38.71±3.81 41.67±9.90 
FEV1 69.72±4.52 54.5±6.79 44.64±4.10 26.71±6.61 
FEV1/FVC 95.24±7.51 94.84±15.14 87.29±6.67 63.14±6.05 
 
Mean FVC is <80% and mean FEV1/FVC <70% indicating the pattern of 
damage is restrictive. 
As the severity of restriction increases value of both FVC and FEV1/ FVC 
declines. 
FEV1 value is < 80% but decrease in FEV1 is less compared to FVC. 
In mixed pattern FVC, FEV1, FEV1/FVC values are below normal. 
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TABLE X 
FEF 25-75% in various patterns of Lung Function Impairment 
 
Parameter 
Pattern of 
damage 
N Mean ± S.D Minimum Maximum F Sig 
FEF 25-75% 
(Percentage 
of predicted 
value) 
Normal 
Study 13 78 ± 16.85 51 111 
48.75 0.000* 
Mild 
restriction 40 56.6 ± 23.02 19 120 
Moderate 
restriction 32 34.38 ± 12.67 20 73 
Severe 
restriction 14 22 ± 6.06 11 32 
Mixed 
pattern 21 12.95 ± 3.49 7 19 
Total 120 41.32 ± 26.0 7 120 
 
Statistical analysis was done by ANOVA. 
Significant difference (P < 0.01) in FEF 25 – 75 % value between different 
pattern of Lung Function Impairment was noted. 
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Figure 12: FEF 25-75% in various patterns of Lung Function Impairment 
 
 
 
 Mean value of FEF 25-75% in various patterns of Lung Function Impairment is 
well below 65% in restrictive and mixed pattern. 
As severity of lung impairment increases mean value of FEF 25-75% decreases 
significantly. 
Significant difference in mean value of FEF 25-75% between restrictive and 
mixed pattern was observed 
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TABLE XI 
Relationship between Duration after Treatment and pattern of 
Lung Function Impairment  
 
Parameter 
Pattern 
of 
damage 
N Mean ± S.D Minimum Maximum F Sig 
DURATION 
AFTER 
TREATMENT 
(MONTHS) 
Normal 
study 13 43.15 ± 13.02 24 60 
7.144 0.000* 
Mild 
restriction 40 34.18 ± 11.0 18 60 
Moderate 
restriction 32 37.12 ± 13.55 19 60 
Severe 
restriction 14 41 ± 16.60 18 60 
Mixed 
pattern 21 51.43 ± 10.25 24 60 
Total 120 39.75 ± 13.79 18 60 
 
Statistically significant variation was seen between each pattern of damage 
and duration after treatment (P<0.01) . 
As duration after treatment increases severity of lung function imapirment 
increases. 
Few subjects ( n=13) showed normal study as duration after treatment 
increases. 
Analysis was done by ANOVA. 
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TABLE XII 
Relationship between Lag time and pattern of Lung Function Impairment 
 
Parameter 
Pattern 
of 
damage 
N Mean ± S.D Minimum Maximum F Sig 
Lag time 
(days) 
Normal 
study 13 49.62 ± 15.47 30 75 
39.22 0.000* 
Mild 
restriction 40 60.75 ± 29.41 30 120 
Moderate 
restriction 32 171.72 ± 95.34 30 365 
Severe 
restriction 14 195 ± 72.30 60 330 
Mixed 
pattern 21 254.76 ± 81.51 60 365 
Total 120 138.75 ± 101.57 30 365 
 
ANOVA shows significant variation between each pattern of Lung Function 
Impairment and lag time (P<0.01) . 
As lag time increases the lung function impairment is more severe. 
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TABLE XIII 
Frequency distribution of Number of Episodes of Anti-TB treatment. 
No. of Episode 
Frequency 
(n=120) 
Percent 
(100) 
1 77 64.2 
2 38 31.7 
3 5 4.2 
 
The above table shows higher percentage of subjects had taken single 
episode of  Anti-TB treatment. 
 
Figure 13 :  Frequency distribution of Number of Episodes of Anti-TB 
Treatment. 
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TABLE XIV 
Relationship between No. of episodes of Anti-TB treatment and pattern of 
Lung Function Impairment  
No Of 
Episodes 
Normal 
Study 
Mild 
Restriction 
Moderate 
Restriction 
Severe 
Restriction 
Mixed 
Pattern 
Total 
Chi 
sq 
P 
value 
1 13 34 21 4 5 77 
42.19 0.000* 
2 0 6 11 8 13 38 
3 0 0 0 2 3 5 
Total 13 40 32 14 21 120 
 
The table shows as number of episodes of Anti-TB treatment increases the 
severity of damage increases. 
This was statistically analysed by chi square test. 
P value is highly significant (P<0.01) . 
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TABLE XV 
Correlation between FVC and No. of Episodes of Treatment, Duration after 
Treatment and Lag Time. 
 
Parameter Correlation 
No. Of 
episodes 
Duration after 
treatment 
Lag time 
FVC 
(Percentage of 
predicted 
value) 
Correlation 
coefficient 
-0.50 -0.90 -0.69 
Sig. (2-tailed) P=0.000* P=0.000* P=0.000* 
 
Analysis done by Spearman’s rho analysis.. 
Significant negative correlation between FVC,and No. of episodes of 
treatment , duration after treatment and lag time was found (P<0.01) .  
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Figure 14 
Correlation between FVC and No. of Episodes of  Treatment 
 
 
 
 
 
 
 
 
 
 The centre line in the above scattered diagram indicates negative correlation 
was observed between FVC and number of episodes of treatment. 
 The lines above and below indicates confidence limit. 
As number of episodes increase there is decrease in FVC value. 
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Figure 15 
Correlation between FVC and Duration After Treatment 
 
Centre line indicates negative correlation was observed between FVC and 
duration after treatment. 
The distribution out of confidence limit is minimal. 
FVC decreases as duration after treatment increases. 
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Figure 16 
Correlation between FVC and Lag Time 
 
Significant negative correlation was observed between FVC and lag time. 
As time duration between onset of symptoms and diagnosis of tuberculosis 
increases there is significant decrease in FVC parameter. 
The distribution of variable is clustered around centre line. 
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TABLE XVI 
Correlation between FEV1 and No. of Episodes of Treatment, Duration After 
Treatment And Lag Time 
 
Parameter Correlation 
No. Of 
episodes 
Duration after 
treatment Lag time 
FEV1 
(Percentage of 
predicted value) 
Correlation 
coefficient -52 -0.95 -0.71 
Sig. (2-
tailed) P=0.000* P=0.000* P=0.000* 
 
Negative correlation between FEV1 and No. of episodes of treatment, 
duration after treatment and lag time was found. 
Correlation was significant (P<0.01) . 
Analysis done by Spearman’s rho analysis. 
  
63 
 
 
Figure 17 
Correlation between FEV1 and No. of Episodes of Treatment. 
 
 
Negative correlation was observed between FEV1 and number of epidoses of 
anti-TB treatment. 
Higher percentage os subjects had taken single episode of of anti-TB 
treatment. 
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Figure 18 
Correlation between FEV1 and Duration After Treatment . 
 
Negative correlation was observed between FEV1 and duration after 
completion of  Anti-TB treatment. 
 The negative correlation is less compared to number of episodes of 
treatment. 
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Figure 19 
Correlation between FEV1 and Lag Time 
 
Negative correlation was observed between FEV1 and lag time. 
As lag time increases there is decrease in FEV1 parameter. 
Distribution outside the confidence limit is minimal. 
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TABLE XVII 
Correlation between FEV1 / FVC and No. of Episodes of Treatment, Duration 
After Treatment and Lag Time 
Parameter Correlation 
No. Of 
episodes 
Duration after 
treatment 
Lag time 
FEV1 / FVC 
(percentage of 
predicted value) 
Correlation 
coefficient 
-0.35 -0.61 -0.403 
Sig. (2-tailed) P=0.000* P=0.000* P=0.000* 
 
Spearman’s rho analysis shows there is significant negative correlation 
between FEV1 / FVC  and No. of Episodes of Treatment, Duration After Treatment 
and Lag Time (P<0.01). 
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Figure 20 
Correlation between FEV1 / FVC and No. of Episodes of Treatment. 
 
Negative correlation was observed between FEV1 / FVC and number of 
epidoses of anti-TB treatment. 
Correlation line is less steep compared to correlation between FVC , FEV1 
and number of episodes of anti-TB treatment. 
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Figure 21 
Correlation between FEV1 / FVC and Duration After Treatment. 
 
Negative correlation was observed between FEV1 / FVC and duration after     
Anti-TB treatment. 
Distribution is not much clustered around centre line as in FVC and FEV1. 
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Figure 22 
Correlation between FEV1 / FVC and Lag Time  
 
Negative correlation was observed between FEV1 / FVC and lag time. 
Distribution outside confidence limit is minimal. 
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TABLE XVIII 
Correlation between FEF 25-75% and No. of Episodes of Treatment, Duration 
After Treatment And Lag Time . 
Parameter Correlation 
No. Of 
episodes 
Duration after 
treatment 
Lag time 
FEF 25-75% 
(Percentage of 
predicted value) 
Correlation 
coefficient -0.48 -0.85 -0.66 
Sig. (2-tailed) P=0.000* P=0.000* P=0.000* 
 
Spearman’s rho analysis shows there is significant negative correlation 
between      FEF25-75% and No. of Episodes of Treatment, Duration After Treatment 
and Lag Time (P<0.01) . 
  
71 
 
 
 
Figure 23 
Correlation between FEF 25-75% and No. of Episodes of Treatment 
 
 
Negative correlation was observed between FEF 25-75% and number of 
epidoses of Anti-TB treatment. 
Higher percentage of subjects had taken single episode of of anti-TB 
treatment. 
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Figure 24 
Correlation between FEF 25-75% and Duration After Treatment 
 
Negative correlation was observed between FEF 25-75% and duration after 
Anti-TB treatment. 
Distribution is much less clustered around centre line but distribution outside 
confidence limit is minimal. 
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Figure 25 
Correlation between FEF 25-75% and Lag Time 
 
Negative correlation was observed between FEF 25-75% and lag time. 
Distribution is more clustered around centre line but distribution outside 
confidence limit is minimal. 
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DISCUSSION 
 Tuberculosis is a worldwide public health problem with higher morbidity 
and mortality among all chronic infections. India alone accounts for 24% of global 
burden of Tuberculosis. 
(2) 
 Pulmonary Tuberculosis affects almost all parts of the respiratory system 
including bronchi, bronchioles, lung parenchyma and lymph nodes. The 
pathogenesis involved is an inflammatory process causing upregulation of several 
proteases like matrix metalloproteinases and dysregulation of protease control 
which causes lung remodeling 
(3) 
Histopathological abnormalities occur even after successful treatment of the 
disease causing sequelae changes in the lungs which can be in the form of fibrosis, 
cavity formation, bronchial and bronchiolar obstruction, bronchiectasis etc. These 
sequelae changes in the respiratory tract can cause obstructive, restrictive or mixed 
pattern of lung function impairment. 
(3)
 
 Many studies have shown that the common pattern of lung function 
impairment in pulmonary TB sequelae patients was obstructive in nature. But the 
recent studies have shown that restrictive pattern and mixed pattern are most 
commonly observed rather than obstructive pattern in these patients. 
(3) 
 All these changes result in abnormal gas exchange which not only affects the 
respiratory system but indirectly leads to frequent comorbidities in post treatment 
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period. Dysfunction involving other systems like cardiovascular system, skeletal 
muscles is common in post tuberculosis treatment period. 
(53)
 
All these factors have a negative effect on quality of life of a patient who had 
been treated for tuberculosis with successful therapy, so it is essential to assess the 
impairment of lung function as early as possible for an early intervention. (55, 58)  
In the present study the age group of selected subjects was between 30 – 60 
years but it was observed that more number of patients fall in the age group of 51 -
60 years (44%) compared to 26% who belonged to age group 30-40 years. This may 
be because normally there is gradual decline in pulmonary function after the age of 
30 years. 
(25) In Tuberculosis affected elderly individual there is an accelerated 
decline of lung function noticed especially over the age of 40. 
(54)
 
More number of male patients participated in the present study compared to 
female patients (Male-81, Female-39). There is evidence in global TB report 2014 
which states that 60% of new cases reported every year belong to male gender. (2) 
The gender difference is may be due to the fact that less number of women 
approaches for medical aid compared to men. The other factors contributing to 
increased susceptibility to TB infection in male gender are the habit of tobacco use 
either by smoking, tobacco quid is common among them and also the risk of 
exposure to the infection and passive smoking   in working environment is more for 
men compared to women. 
In the present study, smoking was not discussed as a significant predictor for 
lung function impairment because all the males who participated in the study had 
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quitted smoking just after the diagnosis of pulmonary tuberculosis and none of the 
women had a history of smoking before and after the attack of Tuberculosis.  
PATTERN OF LUNG FUNCTION IMPAIRMENT 
The pattern of lung function impairment observed in the study were 
restrictive pattern and mixed pattern only. The probable reason for this may be the 
increase in lag time period i.e. the time duration between onset of respiratory 
symptoms and the time of diagnosis as Tuberculosis. 
 There is concrete evidence that as the lag time increases the extent of 
damage to lung also increases. 
(48)
 The Lag time in this study varies from a 
minimum of 30 days to maximum of 365 days. This may be because most of the 
patients are asymptomatic or may experience minimal symptoms like fever and 
malaise ordinarily until disease is far advanced especially during primary 
Tuberculosisi.  (47) Another cause may be the subjects participated in the study were 
from rural areas with poor health education and poor socioeconomic status which 
hampers them to access medical aid as early as they experienced symptoms. This 
increased Lag time might have been the cause for extensive damage resulting in 
restrictive or mixed pattern. 
Few subjects in the study (13 out of 120) had a normal pattern in spirometry. 
This may be due to different factors such as they might have had better pulmonary 
function prior to attack of tuberculosis compared to subjects who showed 
restrictive/mixed pattern. The occupational and environmental exposure might have 
been less compared to other subjects. 
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According to Mohammed Saleh Al- Hajjaj a continuous healing process is 
taking place in the lungs even after completion of treatment. This may also be the 
cause for normal study in these patients. 
(54)
 
FEV1/FVC RATIO 
 The ratio in all types of impairment is well above 70% suggesting the pattern 
of damage is restrictive in nature. The severity of restrictive pattern of damage was 
assessed based on FVC value. (25)  Accordingly, the severity varied from mild to 
moderate to severe restriction in the present study  
  And also it was observed that there is decline in FVC & FEV1 values 
depending upon the severity of lung impairment. This is in consistent with a study 
by Luiz Carlos  D’Aquino et al who says that interpretation of restrictive pattern 
identified by Spirometry can be made more accurate by incorporating the 
magnitude of reduction in FVC and elevated FEV1/FVC ratio. 
(46) 
FVC & FEV1 
 In the present study a significant decrease in FVC & FEV1 was noted as 
severity of restriction increases. Decline in FVC value was more compared to 
decline in FEV1. This is in consistent with a study by Eun Jo Lee et al who found 
that there is negative correlation between FVC and FEV1 values and extent of Lung 
damage. (56)   
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Venkateshiah et al in their study had also stated the usefulness of both FVC 
& FEV1 values in evaluating the extent of destruction of lung. According to them 
the FVC and FEV1 decline as severity of damage increase. 
(47) 
  In mixed pattern where both obstructive and restrictive damage occurs and 
there is significant decrease in FVC and FEV1. and the value of FEV1/FVC is 
around 63% which is well below 70%. (25) 
FEF 25-75% 
The decline in value of FEF 25-75% below 65% in both restrictive and mixed 
pattern of damage in this study indicates there was significant smaller airway 
obstruction in these subjects. This is consistent with finding of Eric Walter Pefura-
Yone et al who suggest that FEF 25-75% <65% is a useful criterion for diagnosis of 
small airway obstruction in treated pulmonary TB patients who had restrictive 
/mixed pattern. They also suggested that decrease in FEF 25-75% is associated with 
poor profile of other spirometry indices like FVC & FEV1. This was also observed 
in the present study. (48) 
The pathogenesis of small airway obstruction is due to destruction of 
parenchyma surrounding the distal small airways by fibrosis causes the loss of 
radial traction on the airways thereby causing distortion and narrowing of these 
small airways. 
(48) 
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DURATION AFTER TREATMENT AND LUNG FUNCTION 
IMPAIRMENT 
In the present study there was negative correlation between pulmonary 
function parameters and duration after treatment. There is controversial evidence in 
studies regarding the relationship between duration after completion of treatment 
and decline of lung function. 
  Some studies say that the nadir of pulmonary function impairment occurs at 
around 18 months after completion of treatment and as duration after treatment   
increases thereafter the severity of damage also increases. 
(3).
 Vargha .G  also 
confirms this in a fifteen year follow up study on both obstructive and  
non- obstructive Pulmonary Tuberculosis patients in which they have noted that 
there is considerable decline of Lung function year after year after completion of 
treatment.
(4) 
According to Mohammed Al-Hajjaj that lung function improves as duration 
after treatment increases because of continuous healing process. 
(54) This was also 
observed in the present study in a minor group (only13 subjects) who had normal 
study pattern in Spirometry even though the mean duration after treatment for them 
was around 43 months compared to subjects who had severe restriction whose mean 
duration after treatment was around 41 months only. 
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LAG TIME AND LUNG FUNCTION IMPAIRMENT 
In the present study a negative correlation between lag time and values of 
pulmonary function parameters was observed. This is similar to the study by Eric 
Walter who states that long duration prior to TB diagnosis is an important 
predictive factor for persisting respiratory signs following successful treatment. 
Delay in diagnosis of TB has shown a direct relationship with severity of 
pulmonary damage. 
(48)  
NUMBER OF EPISODES OF TREATMENT AND LUNG FUNCTION 
IMPAIRMENT 
Negative correlation was observed between decline in Lung function 
parameters and number of episodes of TB treatment in this study. This is consistent 
with Eva Hnizdo et al who had quantified the loss of lung function and their relation 
with number of episodes of Tuberculosis treatment. They say that the increase in 
number of episodes of treatment corresponded with increase in loss of lung 
function. 
(33) 
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LIMITATIONS 
 
1. This is a retrospective study and all the data obtained for the study like treatment 
history, personal history, etc.  Except the investigations were collected from old 
records of the subjects. 
2. Interpretation of restrictive and mixed pattern of lung function impairment can 
be made more accurate by measuring Total Lung Capacity, Functional Residual 
Capacity and Residual Volume by Pulmonary Function Tests other than 
Spirometry. 
3. Periodical follow-up studies at regular intervals with Spirometry can completely 
assess the impairment of lung function.  
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CONCLUSION 
 
The present study shows that because of the marked residual changes in the 
Lung caused by Tuberculosis infection, there occurs a considerable and significant 
decline in Lung function in post treatment period.  
In this study the pattern of impairment of lung function noticed was 
restrictive pattern,  mixed pattern and the extent of impairment increases as lag 
time, number of episodes of treatment and duration after treatment increases.  
As we have limited resources for the management of restrictive and mixed 
pattern of impairment it is essential that an early and effective intervention is 
necessary for detection, diagnosis and compliance of treatment in pulmonary 
tuberculosis affected individuals. 
  This study again like many other studies stresses that even after successful 
completion of anti-Tuberculosis treatment, a regular periodical assessment of 
pulmonary functions with simple and feasible method like Spirometry and addition 
of Pulmonary Rehabilitation Program along with Anti Tuberculosis treatment is 
necessary to improve the Quality of Life of the individuals affected by Pulmonary 
Tuberculosis to a greater extent which helps them to lead a symptomless, 
comfortable and fruitful life in future.    
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SUMMARY 
 The present study was done to analyze the pattern of Lung function impairment 
in Pulmonary Tuberculosis sequelae patients. 
 120 subjects both male and female of age group 30-60 years attending Thoracic 
Medicine outpatient department participated in the study. 
 Spirometry was done for the study group using Easy On PC spirometer in the 
outpatient department itself. 
 Both Flow vs Time Graph and Flow Volume Loop were recorded. Percentage of 
predicted values of FVC, FEV1, FEV1/FVC AND FEF 25-75% were taken for 
analysis. 
 Restrictive pattern and mixed pattern of Lung Function Impairment was 
observed in majority of the subjects. Few subjects (13 out of 120) showed 
normal study in spirometry. 
 This study proves that residual damage do occur in Lungs even after completion 
of Anti- Tuberculosis treatment and the severity of residual damage depends 
upon three important factors like lag time, number of episodes of treatment, 
duration after completion of treatment. 
 Hence a regular follow up assessment of Lung function in Pulmonary 
Tuberculosis patients is essential even after successful completion of Anti- TB 
treatment to reduce the morbidity and mortality in these individuals.  
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ANNEXURES 
 
PROFORMA 
Name: 
Age: 
Sex: 
Height: 
Weight: 
Occupation: 
Socioeconomic status: 
Present complaints with duration: 
Past history: 
 H/O pulmonary tuberculosis with duration 
 Duration between diagnosis and start of treatment 
 Adherence to treatment 
 Released from treatment – duration 
 H/O HIV 
 H/O cardiovascular disease 
 H/O any other respiratory illness 
 H/O lung surgery 
 H/O connective tissue disease 
 H/O diabetes mellitus / hypertension 
 
Treatment history: 
 Details of Anti-Tuberculosis treatment 
 Any side effects for the drugs 
 Present treatment 
Personal history: 
 H/O smoking 
 H/O alcoholism 
Family history: 
 H/O similar illness in family members 
Clinical examination: 
 Vital signs 
 General examination 
 Examination of respiratory system 
 Examination of cardiovascular system 
Investigations: 
 Sputum for Acid Fast Bacilli 
 Chest X-ray PA view 
 Electrocardiogram 
 Spirometry  
  
CONSENT FORM 
STUDY DETAIL : 
“FUNCTIONAL EVALUATION IN PULMONARY TUBERCULOSIS 
SEQUELAE PATIENTS IN A TERTIARY CARE CENTRE – 
CHENGALPATTU” 
STUDY CENTRE : 
 THORACIC MEDICINE OP, CHENGALPATTU MEDICAL COLLEGE 
HOSPITAL, CHENGALPATTU. 
PATIENT NAME:     AGE:                  SEX:   
IDENTIFICATION NUMBER: 
I confirm that have understood the purpose of procedure for the above study. 
I have the opportunity to ask question and all my questions and doubts have 
been answered to my satisfaction. 
I understand that my participation in the study is voluntary and that I am free 
to withdraw anytime without giving any reasons, without my legal rights being 
affected. 
I understand that my investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in respect 
to the current study and any further research that may be conducted in relation to it, 
even if I withdraw from the study, I understand that my identity will not be revealed 
in any information released to third parties or published, unless as required under 
the law. I agree not to restrict the use of any data or results that arrives from the 
study. 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team. 
I hereby give consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic test. 
 
 
Signature of investigator                         Signature/Thumb impression of participant 
 
 
 
Date:                    Participant’s address: 
Place: 
 
 
 
 
 
 
 
MASTER CHART 
 
 
 
MASTER CHART 
S NO NAME 
AGE 
(yrs) 
SEX 
HEIGHT 
(cm) 
WEIGHT 
(kg) 
BMI FVC FEV1 FEV1/FVC 
FEF       
25-75% 
DIAGNOSIS 
Lag 
Time 
(days) 
No. of 
Episodes of 
Anti-TB 
Treatment 
Duration 
After 
Treatment 
(months) 
1 DURAIBABU 54 M 142 70 34.7 68 64 106 50 MILD RESTRICTION 30 1 25 
2 KARTHIKEYAN 30 M 152 45 19.5 49 47 104 46 MODERATE RESTRICTION 180 1 19 
3 SULOCHANA 50 F 144 42 20.0 99 89 90 65 NORMAL STUDY 30 1 38 
4 KASTHURI 36 F 149 41 18.5 62 76 82 37 MILD RESTRICTION 30 1 38 
5 MUNUSAMY 57 M 160 52 20.3 49 46 107 23 MODERATE RESTRICTION 180 1 24 
6 MURUGESAN 55 M 157 49 19.9 35 42 90 22 SEVERE RESTRICTION 240 3 24 
7 GANESAN 57 M 157 45 18.3 64 72 89 37 MILD RESTRICTION 75 1 24 
8 HARIRAMAN 50 M 171 62 21.2 46 49 94 73 MODERATE RESTRICTION 270 2 25 
9 VELAYUTHAM 57 M 163 40 15.1 61 68 90 19 MILD RESTRICTION 120 1 37 
10 EZHUMAZHAI 50 M 161 44 17.0 61 68 90 50 MILD RESTRICTION 60 1 36 
11 THENAPPAN 59 M 154 50 21.1 49 43 114 22 MODERATE RESTRICTION 210 1 24 
12 PERIYASAMY 52 M 156 39 16.0 37 22 61 11 MIXED PATTERN 90 2 30 
13 MUTHUKRISHNAN 50 M 158 45 18.0 85 85 101 81 NORMAL STUDY 60 1 24 
14 OSURAAN 51 M 165 68 25.0 68 60 113 26 MILD RESTRICTION 90 2 18 
15 SAKTHIVEL 39 M 164 50 18.6 52 44 118 26 MODERATE RESTRICTION 150 1 40 
16 PARAMANANTHAM 58 M 169 66 23.1 69 70 99 69 MILD RESTRICTION 60 1 54 
17 CHINAPAYYAN 56 M 156 59 24.2 35 20 59 10 MIXED PATTERN 330 2 60 
18 MUMTAJ 56 F 146 36 16.9 95 92 95 68 NORMAL STUDY 30 1 60 
19 PATCHAIYAMMAL 46 F 153 38 16.2 39 35 88 20 SEVERE RESTRICTION 180 2 30 
20 SARASU 50 F 161 51 19.7 55 55 100 52 MODERATE RESTRICTION 60 1 24 
21 GURUNATHAN 55 M 156 44 18.1 80 77 104 62 MILD RESTRICTION 45 1 36 
22 SAROJA 39 F 155 65 27.1 71 69 103 50 MILD RESTRICTION 60 1 42 
23 MARI 55 M 154 35 14.8 41 48 77 15 SEVERE RESTRICTION 210 2 36 
24 DASS 52 M 160 60 23.4 64 72 89 24 MILD RESTRICTION 45 1 44 
25 INDHUMATHY 35 F 148 57 26.0 66 68 97 71 MILD RESTRICTION 30 1 24 
26 MURUGESAN 53 M 147 52 24.1 53 44 120 22 MODERATE RESTRICTION 150 1 36 
27 SRIRANGAN 58 M 157 56 22.7 62 36 58 18 MIXED PATTERN 240 2 60 
28 SELVI 30 F 160 50 19.5 46 32 70 15 MIXED PATTERN 360 2 48 
29 GOVINDAMMAL 50 F 149 56 25.2 59 49 120 29 MODERATE RESTRICTION 240 1 19 
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30 KANNAN 55 M 163 41 15.4 51 49 104 29 MODERATE RESTRICTION 270 1 24 
31 CHINNATHAMBI MARI 57 M 169 36 12.6 29 16 56 7 MIXED PATTERN 270 3 60 
32 
MUNUSAMY 
VEERABATHRAN 
58 M 165 59 21.7 35 43 92 25 SEVERE RESTRICTION 180 2 20 
33 AMIRTHAMMAL 50 F 149 46 20.7 45 40 88 25 SEVERE RESTRICTION 210 1 36 
34 KESAVAN 57 M 169 56 19.6 25 17 70 10 MIXED PATTERN 240 2 60 
35 PARTHASARATHY 42 M 164 49 18.2 42 48 89 29 SEVERE RESTRICTION 240 1 60 
36 ARASAMMAL 42 F 157 35 14.2 42 45 84 20 SEVERE RESTRICTION 120 2 60 
37 ANNAPPAN 51 M 158 46 18.4 67 73 92 33 MILD RESTRICTION 90 1 24 
38 RAJAMMAL 57 F 146 52 24.4 93 94 100 80 NORMAL STUDY 60 1 48 
39 MALLIGA 47 F 153 40 17.1 31 22 71 11 MIXED PATTERN 300 2 44 
40 VELU 55 M 155 49 20.4 60 69 87 120 MILD RESTRICTION 60 1 46 
41 VENGAPPAN 52 M 159 54 21.4 34 48 93 24 SEVERE RESTRICTION 330 3 36 
42 BALARAMAN 60 M 159 45 17.8 72 74 97 73 MILD RESTRICTION 30 1 48 
43 SALAMMAL 52 F 148 70 32.0 42 46 97 31 SEVERE RESTRICTION 270 1 54 
44 VEERARAGHAVAN 60 M 169 49 17.2 40 22 54 12 MIXED PATTERN 330 1 54 
45 DHANASEKARAN 60 M 157 54 21.9 46 52 88 21 MODERATE RESTRICTION 300 1 42 
46 SHANMUGAM 60 M 148 54 24.9 45 58 78 32 MODERATE RESTRICTION 360 1 30 
47 RANGASAMY 57 M 149 46 20.7 48 49 98 32 MODERATE RESTRICTION 210 2 27 
48 KARUMPAYEE 44 F 142 42 20.8 32 20 65 8 MIXED PATTERN 270 3 48 
49 CARMELRAJ 52 M 158 43 17.2 43 51 80 18 SEVERE RESTRICTION 150 2 60 
50 VELU VENKATESAN 38 M 149 40 18.0 35 16 46 8 MIXED PATTERN 360 2 24 
51 MANI 50 M 171 60 20.5 46 62 74 24 MODERATE RESTRICTION 150 1 24 
52 RAJA  45 M 168 54 19.1 51 60 85 47 MODERATE RESTRICTION 60 1 48 
53 PONNUSAMY 40 M 168 68 24.1 52 61 85 46 MODERATE RESTRICTION 30 2 60 
54 RADHA 40 F 153 60 25.6 39 48 97 32 SEVERE RESTRICTION 240 2 24 
55 PUVIARASI 48 F 153 40 17.1 73 76 96 87 MILD RESTRICTION 105 2 36 
56 VADIVEL 60 M 142 40 19.8 52 50 104 40 MODERATE RESTRICTION 210 1 43 
57 NAGAMMAL 59 F 147 35 16.2 47 31 65 13 MIXED PATTERN 270 2 60 
58 KANNIAPPAN 35 M 170 66 22.8 60 72 83 31 MILD RESTRICTION 60 1 48 
59 MOHAN 35 M 155 55 22.9 69 64 108 50 MILD RESTRICTION 30 1 42 
60 KARTHICK 32 M 176 52 16.8 62 68 91 71 MILD RESTRICTION 75 1 60 
61 MANI 32 M 168 50 17.7 34 42 76 11 SEVERE RESTRICTION 90 1 18 
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62 EZHUMAZHAI 51 M 160 68 26.6 80 84 105 51 NORMAL STUDY 30 1 48 
63 SATHYASEELAN 59 M 162 54 20.6 48 30 63 14 MIXED PATTERN 300 1 43 
64 DHANAPAL 53 M 162 69 26.3 53 59 90 37 MODERATE RESTRICTION 300 2 36 
65 RAJU 35 M 159 53 21.3 43 28 66 13 MIXED PATTERN 240 1 56 
66 DEVI 33 F 153 56 23.9 76 80 95 102 MILD RESTRICTION 30 1 36 
67 
KATHAVARAYAN 
THANGAVEL 
57 M 160 56 21.9 66 72 92 76 MILD RESTRICTION 90 1 19 
68 
KATHAVARAYAN 
VELAN 60 M 
164 55 20.4 62 70 89 24 
MILD RESTRICTION 
30 2 42 
69 GAJAPATHY 51 M 170 40 13.8 47 32 67 18 MIXED PATTERN 330 1 60 
70 DHANAPAL MANI 46 M 157 45 18.3 57 61 93 34 MODERATE RESTRICTION 150 2 52 
71 ANTHONYAMMAL 47 F 158 40 16.0 46 58 79 32 MODERATE RESTRICTION 240 1 60 
72 PUSHPA 57 F 147 54 25.0 35 45 89 18 SEVERE RESTRICTION 60 2 56 
73 EZHILARASI 44 F 150 60 26.7 54 58 93 30 MODERATE RESTRICTION 60 2 60 
74 GOVINDAMMAL 39 F 149 38 17.1 63 67 94 46 MILD RESTRICTION 120 1 20 
75 MANOHARAN 48 M 156 54 22.2 68 70 97 82 MILD RESTRICTION 60 1 25 
76 NAGALINGAM 45 M 157 55 22.3 58 37 64 15 MIXED PATTERN 330 3 60 
77 MANI 48 M 155 43 18.0 88 92 105 97 NORMAL STUDY 75 1 51 
78 SINGARAVELU 58 M 154 52 22.0 67 73 92 68 MILD RESTRICTION 90 1 47 
79 KASINATHAN 57 M 152 43 18.6 58 53 109 35 MODERATE RESTRICTION 90 2 27 
80 FATHIMA 30 F 152 68 29.4 61 68 90 51 MILD RESTRICTION 105 2 24 
81 SIVAKUMAR 35 M 172 49 16.6 36 44 82 18 SEVERE RESTRICTION 210 2 60 
82 REVATHY 31 F 156 60 24.7 49 30 61 12 MIXED PATTERN 60 2 49 
83 RAMALINGAM 41 M 163 45 16.9 56 65 86 26 MODERATE RESTRICTION 330 1 24 
84 KUMAR 39 M 160 54 21.1 73 70 104 63 MILD RESTRICTION 90 1 24 
85 RAMESHKUMAR 32 M 170 70 24.2 66 66 100 71 MILD RESTRICTION 60 1 18 
86 RAGHAVAN 58 M 152 55 23.8 55 58 95 20 MODERATE RESTRICTION 240 1 48 
87 VASANTHI 43 F 152 52 22.5 67 72 93 86 MILD RESTRICTION 60 1 36 
88 PANCHATCHARAM 37 M 163 70 26.3 56 66 85 22 MODERATE RESTRICTION 90 1 36 
89 ARUNA 44 F 145 40 19.0 70 66 106 57 MILD RESTRICTION 105 2 39 
90 SARITHA 57 F 139 65 33.6 49 55 89 31 MODERATE RESTRICTION 210 2 52 
91 ANAR 45 F 154 60 25.3 63 67 94 58 MILD RESTRICTION 75 1 36 
92 SHOBHIKA 30 F 153 47 20.1 86 82 96 69 NORMAL STUDY 30 1 57 
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93 SWETHA 38 F 143 52 25.4 74 68 109 46 MILD RESTRICTION 30 1 48 
94 MALARKODI 40 F 150 45 20.0 94 96 102 88 NORMAL STUDY 45 1 42 
95 ANITHA 49 F 151 60 26.3 96 94 98 77 NORMAL STUDY 60 1 48 
96 PALANI 50 M 150 55 24.4 60 65 92 59 MILD RESTRICTION 30 1 21 
97 MURUGAN 50 M 157 54 21.9 81 87 109 98 NORMAL STUDY 60 1 24 
98 KABILAN 50 M 160 54 21.1 52 53 98 56 MODERATE RESTRICTION 45 1 24 
99 KANNAN 57 M 154 50 21.1 83 92 111 111 NORMAL STUDY 60 1 36 
100 VEERASAMY 49 M 140 55 28.1 61 66 92 49 MILD RESTRICTION 60 1 24 
101 VASANTH 51 M 157 50 20.3 76 83 92 96 MILD RESTRICTION 30 1 36 
102 NASEEM 35 M 143 55 26.9 60 72 83 35 MILD RESTRICTION 30 1 24 
103 RAJAGOPAL 60 M 172 52 17.6 63 68 93 31 MILD RESTRICTION 105 1 26 
104 PAVULUS 57 M 156 44 18.1 72 68 106 36 MILD RESTRICTION 30 1 24 
105 JEYANTHI 37 F 142 70 34.7 54 50 108 38 MODERATE RESTRICTION 90 2 48 
106 KUPPAN 46 M 159 40 15.8 48 33 69 18 MIXED PATTERN 270 2 60 
107 MUNIAMMAL 45 F 145 45 21.4 51 66 77 29 MODERATE RESTRICTION 75 2 25 
108 CHANDRASEKAR 58 M 158 69 27.6 61 68 90 64 MILD RESTRICTION 30 2 38 
109 KUMAR 32 M 175 63 20.6 87 81 93 65 NORMAL STUDY 60 1 25 
110 RADHA 32 F 168 67 23.7 55 51 108 33 MODERATE RESTRICTION 180 2 36 
111 SUDHA 35 F 151 70 30.7 90 85 94 64 NORMAL STUDY 45 1 60 
112 MUNEESWARI 30 F 154 70 29.5 61 66 92 66 MILD RESTRICTION 30 1 30 
113 SHANKARI 32 F 168 68 24.1 64 64 100 38 MILD RESTRICTION 45 1 48 
114 RAVI 48 M 160 70 27.3 36 24 67 11 MIXED PATTERN 180 2 46 
115 GOTHANDAM 47 M 168 58 20.5 55 56 98 61 MODERATE RESTRICTION 30 1 36 
116 SHANKARI 50 F 160 65 25.4 29 30 63 14 MIXED PATTERN 150 2 48 
117 VELLAPPAN 57 M 158 60 24.1 51 32 64 15 MIXED PATTERN 210 2 50 
118 VEERABATHIRAN 55 M 169 63 22.1 53 66 80 29 MODERATE RESTRICTION 270 1 60 
119 MANNU 55 M 170 70 24.2 26 51 51 23 MODERATE RESTRICTION 60 1 55 
120 RADHAKRISHNAN 55 M 168 51 18.1 47 31 67 19 MIXED PATTERN 120 1 60 
 
